References
Bassetti M, Garnacho-Montero J, Calandra T et al (2017) Intensive Care medicine research agenda on invasive fungal infection in critically ill patients. Intensive Care Med 43:1225–1238. https://doi.org/10.1007/s00134-017-4731-2
Maubon D, Garnaud C, Calandra T et al (2014) Resistance of Candida spp. to antifungal drugs in the ICU: where are we now? Intensive Care Med 40:1241–1255. https://doi.org/10.1007/s00134-014-3404-7
Alexander BD, Johnson MD, Pfeiffer CD et al (2013) Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 56:1724–1732. https://doi.org/10.1093/cid/cit136
Pfaller MA, Castanheira M, Lockhart SR et al (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199–1203. https://doi.org/10.1128/JCM.06112-11
Pham CD, Iqbal N, Bolden CB et al (2014) Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 58:4690–4696. https://doi.org/10.1128/AAC.03255-14
Klotz U, Schmidt D, Willinger B et al (2016) Echinocandin resistance and population structure of invasive Candida glabrata isolates from two university hospitals in Germany and Austria. Mycoses 59:312–318. https://doi.org/10.1111/myc.12472
Marcos-Zambrano LJ, Escribano P, Sanchez C et al (2014) Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. Antimicrob Agents Chemother 58:4565–4572. https://doi.org/10.1128/AAC.02670-14
Delliere S, Healey K, Gits-Muselli M et al (2016) Fluconazole and echinocandin resistance of candida glabrata correlates better with antifungal drug exposure rather than with MSH2 mutator genotype in a french cohort of patients harboring low rates of resistance. Front Microbiol 7:2038. https://doi.org/10.3389/fmicb.2016.02038
Scapaticci M, Bartolini A, Del Chierico F et al (2018) Phenotypic typing and epidemiological survey of antifungal resistance of Candida species detected in clinical samples of Italian patients in a 17 months’ period. Germs 8:58–66. https://doi.org/10.18683/germs.2018.1132
Castanheira M (2018) Fungemia surveillance in Denmark demonstrates emergence of non-albicans Candida species and higher antifungal usage and resistance rates than in other nations. J Clin Microbiol 56:e01907–e01917. https://doi.org/10.1128/JCM.01907-17
Singh A, Healey KR, Yadav P et al (2018) Absence of azole or echinocandin resistance in Candida glabrata isolates in India despite background prevalence of strains with defects in the DNA mismatch repair pathway. Antimicrob Agents Chemother. https://doi.org/10.1128/AAC.00195-18
Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(Suppl 6):S612–S617. https://doi.org/10.1093/cid/civ791
Arendrup MC, Patterson TF (2017) Multidrug-resistant Candida: epidemiology, molecular mechanisms, and treatment. J Infect Dis 216:S445–S451. https://doi.org/10.1093/infdis/jix131
Shields RK, Nguyen MH, Clancy CJ (2015) Clinical perspectives on echinocandin resistance among Candida species. Curr Opin Infect Dis 28:514–522
Schell WA, Jones AM, Borroto-Esoda K, Alexander BD (2017) Antifungal activity of SCY-078 and standard antifungal agents against 178 clinical isolates of resistant and susceptible Candida species. Antimicrob Agents Chemother 62:e00195-18. https://doi.org/10.1128/AAC.01102-17
Kohlenberg A, Struelens MJ, Monnet DL, Plachouras D (2018) Candida auris: epidemiological situation, laboratory capacity and preparedness in European Union and European Economic Area countries, 2013 to 2017. Euro Surveill. https://doi.org/10.2807/1560-7917.ES.2018.23.13.18-00136
Chowdhary A, Sharma C, Meis JF (2017) Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog 13:e1006290. https://doi.org/10.1371/journal.ppat.1006290
https://www.cdc.gov/fungal/diseases/candidiasis/tracking-c-auris.html. Accessed 6 May 2018
Lockhart SR, Etienne KA, Vallabhaneni S et al (2017) Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis 64:134–140. https://doi.org/10.1093/cid/ciw691
Ku TSN, Walraven CJ, Lee SA (2018) Candida auris: disinfectants and implications for infection control. Front Microbiol 9:726. https://doi.org/10.3389/fmicb.2018.00726
Kordalewska M, Lee A, Park S et al (2018) Understanding echinocandin resistance in the emerging pathogen Candida auris. Antimicrob Agents Chemother 62:e00238-18. https://doi.org/10.1128/AAC.00238-18
Chowdhary A, Prakash A, Sharma C et al (2018) A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009–2017) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother 73:891–899. https://doi.org/10.1093/jac/dkx480
Hager CL, Larkin EL, Long LA, Ghannoum MA (2018) Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model. J Antimicrob Chemother 73:2085–2088. https://doi.org/10.1093/jac/dky153
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Cortegiani, A., Misseri, G. & Chowdhary, A. What’s new on emerging resistant Candida species. Intensive Care Med 45, 512–515 (2019). https://doi.org/10.1007/s00134-018-5363-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-018-5363-x